Conclusively, Mettl-3 is key player in reducing the efficacy of anti-PD-1 therapy, and therefore targeting (overexpressing) Mettl-3 could be a promising approach to control cancer metastasis by enhancing the efficacy of anti-PD-1 antibodies (Figure 4) [9]. This evidence concerns the gene PDCD1 and cancer.